MEDICINES NOTIFICATION

CLASS 4 MEDICINES DEFECT INFORMATION, EL(26)A/35

Caution In Use

Issued 20 July 2026

Distribute to Pharmacy/Wholesaler Level

MARKETING AUTHORISATION HOLDER (MAH)

Macarthys Laboratories Ltd Trading as Martindale Pharma

MEDICINE DETAILS

Xaggitin XL 18 mg Prolonged-release Tablets
PL: **01883/0359**
Active Ingredient: **methylphenidate hydrochloride**
SNOMED code: **34248211000001101**
GTIN: **05060078672023**

AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
183155	30/10/2027	30 tablets	17/03/2026
185442	31/12/2027	30 tablets	Not yet distributed

MEDICINE DETAILS

Xaggitin XL 27 mg Prolonged-release Tablets
PL: **01883/0360**
Active Ingredient: **methylphenidate hydrochloride**
SNOMED code: **34248911000001105**
GTIN: **05060078670227**

AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
174975	31/05/2027	30 tablets	18/02/2026
175037	31/05/2027	30 tablets	21/05/2026
178223	31/07/2027	30 tablets	17/04/2026
183931	30/11/2027	30 tablets	Not yet distributed
185438	30/11/2027	30 tablets	Not yet distributed
185439	30/11/2027	30 tablets	Not yet distributed
185440	30/11/2027	30 tablets	07/04/2026
187560	28/02/2028	30 tablets	Not yet distributed

MEDICINE DETAILS

Xaggitin XL 36 mg Prolonged-release Tablets
PL: **01883/0361**
Active Ingredient: **methylphenidate hydrochloride**
SNOMED code: **34248411000001102**
GTIN: **05060078672030**

AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
175426	30/06/2027	30 tablets	12/03/2026
175428	30/06/2027	30 tablets	18/05/2026
176698	30/06/2027	30 tablets	17/03/2026
176699	30/06/2027	30 tablets	Not yet distributed
176700	30/06/2027	30 tablets	Not yet distributed
182875	30/09/2027	30 tablets	06/05/2026
183003	31/10/2027	30 tablets	Not yet distributed

MEDICINE DETAILS

Xaggitin XL 54 mg Prolonged-release Tablets

PL: **01883/0362**

Active Ingredient: **methylphenidate hydrochloride**

SNOMED code: **34248711000001108**

GTIN: **05060078672047**

AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
178338	31/07/2027	30 tablets	09/02/2026
178432	31/07/2027	30 tablets	31/03/2026
178481	31/07/2027	30 tablets	18/05/2026
180343	30/09/2027	30 tablets	08/06/2026
187926	28/02/2028	30 tablets	03/07/2026
187927	28/02/2028	30 tablets	Not yet distributed
187928	28/02/2028	30 tablets	Not yet distributed
187929	28/02/2028	30 tablets	Not yet distributed
187930	28/02/2028	30 tablets	Not yet distributed

Background

Macarthys Laboratories Ltd T/A Martindale Pharma has notified the MHRA of a manufacturing issue impacting several batches of Xaggitin XL Prolonged-release Tablets, due to the occurrence of incorrect tablet counts in the bottles. Multiple complaints of incorrect quantities of tablets in packs of Xaggitin XL Prolonged-release Tablets have been received. The majority of reports are for missing tablets but extra tablets have also been reported.

The batches listed as ‘not yet distributed’ may be impacted by the same issue. The MHRA, in discussion with the Department of Health and Social Care, considers these products critical for patients, therefore these batches will not be repackaged and continue to be distributed. They are therefore included in the notification.

The defect appears to be impacting a low percentage of packs within a batch, impacting reconciliation of the Schedule 2 Controlled Drug in practices.

The quality of the tablets is not impacted by this defect and therefore the product is not being recalled.

Advice for Healthcare Professionals:

Please physically check the quantity of tablets when receiving the packs and when dispensing these tablets, this may include breaking the tamper evident seal. Please report any affected packs to licensed@ethypharm.com using the reference Ethypharm supply for any reconciliation excursions experienced due to this defect.

Be aware that patients may return for their next prescription earlier than expected.

Advice for Patients:

Patients should be aware that some packs of the affected batches may have an incorrect number of tablets in the bottle, leading to missing or additional tablets.

Patients may continue to take the tablets prescribed by your doctor as the quality of the tablets is not impacted by this defect.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Additional information:

For all medical information enquiries and information on this product, please email medinfo@ethypharm.com or telephone 01277 266 600 Selecting Option 2.

For stock control enquiries please email licensed@ethypharm.com, or telephone 01628 551900.

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU

Telephone +44 (0)20 3080 6574

DMRC@mhra.gov.uk